Myotonic Dystrophy Clinical Trial
Official title:
Lung Function Impairment and Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients
Myotonic dystrophy Type 1 (MD1, Steinert's disease), an autosomal dominant multisystem
disease, is of the most common muscular dystrophies in adults, with a European prevalence of
3-15/100 000. The disease course is progressive, associating muscular weakness, wasting and
myotonia. Respiratory dysfunction is common, involving a restrictive ventilatory abnormality
and alveolar hypoventilation, originating from respiratory muscle weakness. Depending on the
degree of impairment of their lung function, the quality of life and the prognosis of MD1
patients may be very variable. However, time course and prevalence of such respiratory
function impairment have not been clearly identified. More importantly, factors able to
predict poor respiratory outcome have not been defined and therefore early prognosis can not
be assessed during the follow-up of these patients. In other neuromuscular disorders,
especially Amyotrophic Lateral Sclerosis (ALS), postural spirometry has been recommended to
improve the detection of diaphragmatic involvement and some authors have suggested that the
supine fall in the forced vital capacity could be used to initiate noninvasive positive
pressure ventilation and predicts some respiratory symptoms.
In a sample of ambulatory patients with MD1, our study was designed to prospectively achieve
two aims: 1) to assess the respective prevalence of a ventilatory restrictive pattern,
respiratory muscle weakness, hypoxemia and hypercapnia and 2) to evaluate whether postural
changes in lung volumes contribute to sensitize the diagnosis of respiratory weakness and
could be used as a predictor of poor respiratory function, including hypoxemia, hypercapnia
and restrictive ventilatory disease.
Materials and Methods :
Subjects:
Adult ambulatory patients (18 years of age and older) with a clinical diagnosis of myotonic
dystrophy type I were investigated prospectively as part of routine follow-up, from april
2008 to june 2010. Patients were clinically evaluated in the department of "Internal
Medicine" and lung function was assessed in the department of "Pulmonary Function Testing",
both from the University Hospital of Nancy. Pulmonary tests were ordered for clinical
indications, not part of a study protocol. The supine evaluation was added of the
conventional lung function testing. All individual were examined and categorized according
to a standardized five-point muscular-impairment rating scale, in which a score of 1
indicates no muscular impairment, 2 minimal signs without distal weakness except for digit
flexors, 3 distal weakness without proximal weakness except for elbow extensors, 4 moderate
proximal weakness, and 5 severe weakness (MIRS).
Lung and respiratory muscle function:
All pulmonary function tests met or exceeds applicable standards of the European Respiratory
Society / American Thoracic Society.
Spirometry was performed in the upright-seated position and in the supine position.
Respiratory function data were compared with the predicted normal values obtained by the
European Community for Steel and Coal and expressed as percentage of the normal value. The
flow/volume curve and lung volumes were respectively assessed by an open-circuit spirometry
and plethysmography.
Maximal Inspiratory Pressure (MIP) and Maximal Expiratory Pressure (MEP) were both measured
in the seated position using a standard flanged mouthpiece.MIP was measured from Residual
Volume (RV) and MEP was measured from Total Lung Capacity (TLC), both in a standard manner.
The manoeuvres were repeated at least three times, or until two identical readings were
obtained, and the best value was taken. Respiratory Muscle Strength (RMS) was defined as the
mean of MIP and MEP expressed as a percent of the predicted values.
Arterial sampling and blood gas analysis :
Arterial blood gases were drawn at rest from the radial artery of the nondominant arm while
the patient was comfortably seated for at least 10 minutes. A sterile, self-filling and
disposable pre-heparinized system was used to take 1.5 ml of arterial blood.
Arterial oxygen partial pressure (PaO2) and arterial carbon dioxide partial pressure (PaCO2)
were determined within 10 minutes after sampling. Room temperature and barometric pressure
were recorded on a daily basis and were used to adjust calibrations and measurements.
Quality control of the blood-gas equipment was performed twice a day, using standard
solution.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04624750 -
Open Label Study in Adolescents and Children With Myotonic Disorders
|
Phase 3 | |
Recruiting |
NCT00082108 -
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
|
||
Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
Completed |
NCT05027269 -
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00233519 -
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
|
Phase 1/Phase 2 | |
Completed |
NCT00167609 -
Efficacy and Safety of DHEA for Myotonic Dystrophy
|
Phase 2/Phase 3 | |
Recruiting |
NCT06411288 -
Global Study of Del-desiran for the Treatment of DM1
|
Phase 3 | |
Recruiting |
NCT04003363 -
The United Kingdom National Registry for Myotonic Dystrophy
|
||
Completed |
NCT01136330 -
DM1 Heart Registry - DM1 Respiratory Registry
|
N/A | |
Completed |
NCT02375087 -
Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?
|
||
Completed |
NCT01406873 -
Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
|
Phase 2 | |
Completed |
NCT03959189 -
Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
|
Phase 1 | |
Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
Recruiting |
NCT00127582 -
RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
|
Phase 3 | |
Recruiting |
NCT02398786 -
Myotonic Dystrophy Family Registry
|
||
Recruiting |
NCT05019625 -
Biomarker Development for Muscular Dystrophies
|
||
Recruiting |
NCT05020002 -
Extracellular RNA Biomarkers of Myotonic Dystrophy
|
||
Active, not recruiting |
NCT04616807 -
An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders
|
||
Active, not recruiting |
NCT05479981 -
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
|
Phase 2 | |
Terminated |
NCT02315339 -
European Home Mechanical Ventilation Registry
|